|
CA2213567C
(en)
*
|
1995-02-24 |
2010-01-26 |
Stuart L. Weg |
Use of ketamine for facilitating detoxification and treatment of smoking addiction, and device therefor
|
|
GB0009469D0
(en)
*
|
2000-04-17 |
2000-06-07 |
Vectura Ltd |
Improvements in or relating to formalities for use in inhaler devices
|
|
US20050148673A1
(en)
|
2002-07-11 |
2005-07-07 |
Harbut Ronald E. |
Prolonged administration of NMDA antagonist and safener drug to alter neuropathic pain condition
|
|
MXPA05000294A
(es)
|
2002-07-30 |
2005-08-19 |
Peter Migaly |
Terapia combinada para la depresion, prevencion de suicidios y varias condiciones medicas y psiquiatricas.
|
|
US7985422B2
(en)
|
2002-08-05 |
2011-07-26 |
Torrent Pharmaceuticals Limited |
Dosage form
|
|
US8268352B2
(en)
|
2002-08-05 |
2012-09-18 |
Torrent Pharmaceuticals Limited |
Modified release composition for highly soluble drugs
|
|
WO2004045601A1
(en)
*
|
2002-11-18 |
2004-06-03 |
Yaupon Therapeutics, Inc. |
Analgesic uses of norketamine and ketamine/norketamine prodrugs
|
|
US10172810B2
(en)
|
2003-02-24 |
2019-01-08 |
Pharmaceutical Productions, Inc. |
Transmucosal ketamine delivery composition
|
|
CA2516619A1
(en)
|
2003-02-26 |
2004-09-10 |
Johns Hopkins University |
Glutamate transport modulatory compounds and methods
|
|
EP1613324A2
(en)
|
2003-04-14 |
2006-01-11 |
Pain Therapeutics, Inc. |
Methods for the treatment of pain comprising opioid antagonists
|
|
WO2005102338A1
(en)
|
2004-04-20 |
2005-11-03 |
Pfizer Limited |
Method of treating neuropathic pain using a crth2 receptor antagonist
|
|
WO2006042249A2
(en)
|
2004-10-08 |
2006-04-20 |
Neuromolecular Pharmaceuticals, Inc. |
Methods and compositions for treating migraine pain
|
|
US20080096872A1
(en)
|
2004-12-22 |
2008-04-24 |
Friedman Robert S |
Composition for Treatment of Pain Specification
|
|
MX2007010721A
(es)
|
2005-03-01 |
2007-11-13 |
Pfizer Ltd |
Nuevo uso de inhibidores de fosfodiesterasa 7 para el tratamiento de dolor neuropatico.
|
|
WO2006094797A1
(en)
|
2005-03-04 |
2006-09-14 |
Mentis Cura Ehf. |
A method and a system for assessing neurological conditions
|
|
BRPI0607017B8
(pt)
|
2005-04-06 |
2021-05-25 |
Adamas Pharmaceuticals Inc |
composição farmacêutica compreendendo memantina e donezepil, e seu uso para o tratamento de condições relacionadas ao snc
|
|
GB0523031D0
(en)
*
|
2005-11-11 |
2005-12-21 |
Yaupon Therapeutics |
Enhancement of morphine analgesia by s(-)-norketamine
|
|
JP2009520040A
(ja)
|
2005-12-19 |
2009-05-21 |
ファーマイン コーポレーション |
治療薬の送達のための疎水性コアの担体組成物、及び同担体組成物の作製法及び使用法
|
|
JP2009530385A
(ja)
|
2006-03-22 |
2009-08-27 |
マウント シナイ スクール オブ メディシン |
うつ病の治療のためのケタミンの鼻内投与
|
|
BRPI0711872A2
(pt)
|
2006-05-22 |
2011-12-06 |
Vanda Pharmaceuticals Inc |
tratamento para distúrbios depressivos
|
|
EP1902733A1
(en)
|
2006-09-19 |
2008-03-26 |
Laboratorios Del Dr. Esteve, S.A. |
Combination of a NMDA-receptor ligand and a compound with 5-HT6 receptor affinity
|
|
EP2114150A4
(en)
|
2007-02-01 |
2010-03-10 |
Alan I Green |
COMBINATIONS OF BLOCKING OF DOPAMINERGIC D2 RECEPTORS WITH INHIBITION OF NOREPINEPHRINE RECAPTATION AND BLOCKING OF NOREPINEPHRINE ALPHA RECEPTORS
|
|
DE102007009888A1
(de)
|
2007-02-28 |
2008-09-04 |
Hermann, Holger Lars, Dr. |
Verwendung von S-(+)-Ketamin zur Behandlung von Depressionen
|
|
LT2125698T
(lt)
|
2007-03-15 |
2016-10-10 |
Auspex Pharmaceuticals, Inc. |
Deuterintas d9-venlafaksinas
|
|
WO2008141057A1
(en)
|
2007-05-08 |
2008-11-20 |
Auspex Pharmaceuticals, Inc. |
Deuterated pimavanserin 1- (4-flu0r0benzyl) -3- (4-isobutoxybenzyl) -1- ( l-methyl-piperidin-4-yl) -urea
|
|
US20090004281A1
(en)
|
2007-06-26 |
2009-01-01 |
Biovail Laboratories International S.R.L. |
Multiparticulate osmotic delivery system
|
|
US20100316678A1
(en)
|
2007-06-28 |
2010-12-16 |
Cnsbio Pty Ltd. |
Combination methods and compositions for treatment of neuropathic pain
|
|
CA2698038A1
(en)
|
2007-07-26 |
2009-01-29 |
Entra Pharmaceuticals Inc. |
Systems and methods for delivering drugs
|
|
WO2009021058A2
(en)
|
2007-08-06 |
2009-02-12 |
Trinity Labortories, Inc. |
Pharmaceutical compositions for treating chronic pain and pain associated with neuropathy
|
|
SI2200610T1
(en)
|
2007-09-21 |
2018-06-29 |
Acadia Pharmaceuticals Inc. |
Co-administration of pimavanserin with other agents
|
|
EP2254577A1
(en)
|
2007-12-26 |
2010-12-01 |
Eisai R&D Management Co., Ltd. |
Ampa receptor antagonists for epilepsy, mental disorders or deficits in sensory organ
|
|
US20090198145A1
(en)
|
2008-02-06 |
2009-08-06 |
Chow Harrison |
Compositions, methods, and systems for rapid induction and maintenance of continuous rem sleep
|
|
US20140037718A1
(en)
|
2009-03-06 |
2014-02-06 |
George W. Lutz |
Transdermal pain gel
|
|
GB0908129D0
(en)
*
|
2009-05-12 |
2009-06-24 |
Innovata Ltd |
Composition
|
|
US20120225949A1
(en)
|
2009-08-14 |
2012-09-06 |
Demitri Papalos |
Compositions and methods for treating bipolar disorder
|
|
EP2493457B1
(en)
|
2009-10-30 |
2017-08-09 |
IX Biopharma Ltd |
Fast dissolving solid dosage form
|
|
WO2011086563A2
(en)
|
2010-01-18 |
2011-07-21 |
Elminda Ltd. |
Method and system for weighted analysis of neurophysiological data
|
|
WO2013003669A2
(en)
|
2011-06-30 |
2013-01-03 |
University Of South Florida |
Compositions, methods of use, and methods of treatment
|
|
CN104114714A
(zh)
|
2011-12-14 |
2014-10-22 |
阿斯利康(瑞典)有限公司 |
Gabr-a2诊断
|
|
US20130236573A1
(en)
|
2012-03-12 |
2013-09-12 |
Janssen Pharmaceutica Nv |
Esketamine for the treatment of treatment-refractory or treatment-resistant depression
|
|
JP2015512418A
(ja)
|
2012-03-30 |
2015-04-27 |
ザ ジェネラル ホスピタル コーポレイション |
うつ病の治療におけるスコポラミンおよびケタミンを含む組成物
|
|
US20120323214A1
(en)
|
2012-05-16 |
2012-12-20 |
Totada R Shantha |
Alzheimer's disease treatment with multiple therapeutic agents delivered to the olfactory region through a special delivery catheter and iontophoresis
|
|
WO2014020155A1
(en)
|
2012-08-02 |
2014-02-06 |
Clinpharm Reform Gmbh |
Oral transmucosal adminstration forms of s-ketamine
|
|
SG11201501292UA
(en)
|
2012-08-23 |
2015-05-28 |
Stuart L Weg |
Anxiolytic composition, formulation and method of use
|
|
US8974365B2
(en)
|
2012-11-25 |
2015-03-10 |
Steven Richard Devore Best |
Treatment of thalamocortical dysrhythmia
|
|
EP2938608B1
(en)
|
2012-12-20 |
2021-08-04 |
Sanford-Burnham Medical Research Institute |
Small molecule agonists of neurotensin receptor 1
|
|
EP3498268A1
(en)
|
2013-03-15 |
2019-06-19 |
Janssen Pharmaceutica NV |
Pharmaceutical composition of s-ketamine hydrochloride
|
|
PE20200404A1
(es)
|
2013-03-15 |
2020-02-26 |
Janssen Pharmaceutica Nv |
Composicion farmaceutica de clorhidrato de s-ketamina
|
|
AU2014248455B2
(en)
|
2013-04-01 |
2018-12-06 |
Pulmatrix Operating Company, Inc. |
Tiotropium dry powders
|
|
EP3960162A1
(en)
|
2013-08-26 |
2022-03-02 |
Amorsa Therapeutics, Inc. |
Single-layer oral dose of neuro-attenuating ketamine
|
|
WO2015037248A1
(en)
|
2013-09-13 |
2015-03-19 |
National University Corporation Chiba University |
Application of r-ketamine and salt thereof as pharmaceuticals
|
|
US9610259B2
(en)
|
2014-01-14 |
2017-04-04 |
Children's Hospital Medical Center |
Compositions and methods for treating an autism spectrum disorder
|
|
EP3131533B1
(en)
|
2014-04-17 |
2019-06-05 |
Develco Pharma Schweiz AG |
Oral dosage form of ketamine
|
|
KR20220102662A
(ko)
|
2014-05-06 |
2022-07-20 |
노쓰웨스턴유니버시티 |
Nmdar 조절 화합물의 조합물
|
|
US11207316B2
(en)
|
2014-05-30 |
2021-12-28 |
West Virginia University |
Ketamine or dextromethorphan formulations and methods of use
|
|
US20160008777A1
(en)
|
2014-07-09 |
2016-01-14 |
Novotec Consulting Inc. |
Pharmaceutical compounding kit
|
|
CA2957926A1
(en)
|
2014-08-13 |
2016-02-18 |
Janssen Pharmaceutica Nv |
Method for the treatment of depression
|
|
KR20170054470A
(ko)
|
2014-09-15 |
2017-05-17 |
얀센 파마슈티카 엔.브이. |
VAL66MET (SNP rs6265) 유전자형 특이적 투여 계획 및 우울증 치료 방법
|
|
WO2016057712A1
(en)
|
2014-10-07 |
2016-04-14 |
Lam Therapeutics, Inc. |
An inhalable rapamycin formulation for the treatment of pulmonary hypertension
|
|
EP3215147B1
(en)
|
2014-11-04 |
2024-02-28 |
ACADIA Pharmaceuticals Inc. |
Neuro-attenuating norketamine compounds and methods
|
|
EP3229788A4
(en)
|
2014-12-08 |
2018-06-13 |
Cima Labs Inc. |
Immediate release abuse-deterrent granulated dosage forms
|
|
EP3240422A1
(en)
|
2014-12-31 |
2017-11-08 |
Icahn School of Medicine at Mount Sinai |
Method of maintaining the anti-depressant effect of ketamine with lithium
|
|
US10302625B2
(en)
|
2015-01-15 |
2019-05-28 |
Centre For Addiction And Mental Health |
Peripheral measure of central brain inflammation, markers therefor and uses thereof
|
|
EP3085366A1
(en)
|
2015-04-22 |
2016-10-26 |
Institut du Cerveau et de la Moelle Epiniere-ICM |
Nmda antagonists for the treatment of mental disorders with occurrence of aggressive and/or impulsive behavior
|
|
US20160332962A1
(en)
|
2015-05-13 |
2016-11-17 |
Janssen Pharmaceutica Nv |
(s)-csa salt of s-ketamine, (r)-csa salt of s-ketamine and processes for the preparation of s-ketamine
|
|
WO2016186968A1
(en)
|
2015-05-15 |
2016-11-24 |
The Arizona Board Of Regents On Behalf Of The University Of Arizona |
Compositions and methods for treating motor disorders
|
|
US20160338977A1
(en)
|
2015-05-20 |
2016-11-24 |
Janssen Pharmaceutica Nv |
Methods and kits for treating depression
|
|
CA2988578A1
(en)
|
2015-06-12 |
2016-12-15 |
Indiana University Research & Technology Corporation |
Predicting suicidality using a combined genomic and clinical risk assessment
|
|
AU2016288188B2
(en)
|
2015-06-27 |
2021-08-05 |
Shenox Pharmaceuticals, Llc |
Ketamine transdermal delivery system
|
|
CN106562952B
(zh)
*
|
2015-10-09 |
2020-06-09 |
江阴安博生物医药有限公司 |
氯胺酮在治疗重性抑郁障碍中的应用
|
|
EP3362080A1
(en)
|
2015-10-16 |
2018-08-22 |
Northwestern University |
Pharmaceutical combination of an atypical antipsychotic and an nmda modulator for the treatment of schizophrenia,bipolar disorder, cognitive impairment and major depressive disorder
|
|
WO2017087691A1
(en)
|
2015-11-17 |
2017-05-26 |
The Trustees Of Columbia University In The City Of New York |
Pharmacological prophylactics against stress-induced affective disorders and their associated symptoms
|
|
US10881637B2
(en)
|
2015-11-17 |
2021-01-05 |
Atlee Solomon |
Intranasal and transdermal administration of kappa-opioid-receptor agonists: salvinorin A for the treatment of neuropsychiatric and addictive disorders
|
|
US20180296478A1
(en)
|
2016-02-12 |
2018-10-18 |
Synergistic Therapeutics, Llc |
Sublingual antidepressant and antianxiety tablet
|
|
US20180042936A1
(en)
|
2016-03-18 |
2018-02-15 |
Genomind, Inc. |
Maintenance therapy using tianeptine
|
|
JP2019512528A
(ja)
|
2016-03-25 |
2019-05-16 |
ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ |
抑うつ、不安症、快感消失症、疲労、自殺念慮、および外傷後ストレス障害の治療における（２ｒ，６ｒ）−ヒドロキシノルケタミンおよび（２ｓ，６ｓ）−ヒドロキシノルケタミンの使用方法
|
|
WO2017205666A1
(en)
|
2016-05-25 |
2017-11-30 |
National Health Research Institutes |
Method and composition for decreasing the psychotomimetic side effect and addictive disorder of ketamine
|
|
KR20240027874A
(ko)
|
2016-07-28 |
2024-03-04 |
리제너론 파마슈티칼스 인코포레이티드 |
Gpr156 변이체 및 이들의 용도
|
|
CN109640947A
(zh)
|
2016-08-05 |
2019-04-16 |
株式会社新日本科学 |
鼻内药物粉末组合物
|
|
US20180064655A1
(en)
|
2016-09-06 |
2018-03-08 |
Steven Sounyoung Yu |
Hydroxynorketamine Transdermal Patch
|
|
US10596378B2
(en)
|
2016-10-18 |
2020-03-24 |
Joseph Rustick |
Method for treatment of depression using synaptic pathway training
|
|
US10905897B2
(en)
|
2016-10-20 |
2021-02-02 |
Neuro-Laser Foundation, Inc. |
Synergistic treatment methodologies using light therapy
|
|
IL315066A
(en)
|
2016-10-27 |
2024-10-01 |
Univ Chiba Nat Univ Corp |
Application of (s)-norketamine and salt therof as pharmaceutical
|
|
US20180177743A1
(en)
|
2016-12-22 |
2018-06-28 |
Gary Jay |
Method of treating pain using racemic mixture of s-ketamine and r-ketamine
|
|
US20180177744A1
(en)
|
2016-12-22 |
2018-06-28 |
Gary Jay |
Method of treating pain and depression using a hybrid mixture of s-ketamine and r-ketamine
|
|
AU2018254506A1
(en)
|
2017-04-20 |
2019-10-31 |
Guangzhou Dazhou Biomedicine Ltd. |
Transdermal drug delivery system for ketamine
|
|
EP3635130A4
(en)
|
2017-05-12 |
2021-06-09 |
Indiana University Research and Technology Corporation |
Precision medicine for treating and preventing suicidality
|
|
MX394876B
(es)
|
2017-05-25 |
2025-03-24 |
Glytech Llc |
Formulaciones para el tratamiento del trastorno de estres post-traumatico.
|
|
DE102017112527B4
(de)
|
2017-06-07 |
2019-01-03 |
Lts Lohmann Therapie-Systeme Ag |
Schnell zerfallende Schaumwafer mit hohem Flächengewicht
|
|
WO2018234568A2
(en)
|
2017-06-23 |
2018-12-27 |
Develco Pharma Schweiz Ag |
Hydroxynorketamine for the use in the treatment of depression
|
|
WO2019038756A1
(en)
|
2017-08-20 |
2019-02-28 |
Solubest Ltd. |
DRY POWDER COMPOSITIONS FOR INTRANASAL DELIVERY
|
|
ES2924188T3
(es)
|
2017-09-25 |
2022-10-05 |
Small Pharma Ltd |
Formas sólidas de dosificación oral de derivados de ketamina
|
|
TW201919595A
(zh)
|
2017-09-27 |
2019-06-01 |
國立大學法人千葉大學 |
作為神經變性疾病或認知機能障礙之預防或治療劑之r-氯胺酮及其衍生物
|
|
US12090123B2
(en)
|
2017-10-10 |
2024-09-17 |
Douglas Pharmaceuticals Ltd. |
Extended release pharmaceutical formulation
|
|
WO2019079742A1
(en)
|
2017-10-19 |
2019-04-25 |
Eleusis Benefit Corporation, Pbc |
METHODS AND SYSTEMS FOR IMPROVING THE SAFETY OF PSYCHEDELIC PHARMACOTHERAPIES
|
|
US11491120B2
(en)
|
2017-11-09 |
2022-11-08 |
The Trustees Of Columbia University In The City Of New York |
Pharmacological prophylactics against stress-induced affective disorders in females
|
|
US20200384188A1
(en)
|
2017-11-14 |
2020-12-10 |
Bexson Biomedical, Inc. |
Systems, devices, formulations and methods for controlled drug delivery
|
|
DE102017129012A1
(de)
|
2017-12-06 |
2019-06-06 |
Lts Lohmann Therapie-Systeme Ag |
Oraler Dünnfilm mit hoher Wirkstoffbeladung
|
|
IL275482B1
(en)
|
2017-12-22 |
2025-03-01 |
Janssen Pharmaceuticals Inc |
Esketamine for the treatment of depression
|
|
EP3505157B1
(en)
|
2017-12-29 |
2021-12-08 |
Celon Pharma S.A. |
Dry powder ketamine composition for pulmonary administration in treatment-resistant depression
|
|
RU2756512C1
(ru)
|
2018-01-10 |
2021-10-01 |
ЭксДабл-ЮФАРМА ЛТД. |
Пролекарства кетамина, его композиции и применения
|
|
JP7354123B2
(ja)
|
2018-02-21 |
2023-10-02 |
エイアイ・セラピューティクス・インコーポレーテッド |
アピリモドとグルタミン酸作動薬を用いた併用療法
|
|
US11980617B2
(en)
|
2018-03-16 |
2024-05-14 |
Intra-Cellular Therapies, Inc. |
Methods of treating acute depression and/or acute anxiety
|
|
WO2019186357A1
(en)
|
2018-03-26 |
2019-10-03 |
Cellix Bio Private Limited |
Compositions and methods for the treatment of neurological diseases
|
|
US20230390385A1
(en)
|
2018-04-11 |
2023-12-07 |
Fred M. COWAN |
Compositions and Methods for Prevention and Treatment of Immune Complex Disease
|
|
EP3813808A4
(en)
|
2018-05-04 |
2022-01-26 |
Perception Neuroscience, Inc. |
Methods of treating substance abuse
|
|
US11766409B2
(en)
|
2018-05-31 |
2023-09-26 |
The University Of Queensland |
Core-shell polymer nanoparticle
|
|
GB201809976D0
(en)
|
2018-06-18 |
2018-08-01 |
Neurocentrx Pharma Ltd |
Novel formulations
|
|
EP3813807A1
(en)
|
2018-06-27 |
2021-05-05 |
Clexio Biosciences Ltd. |
Method of treating major depressive disorder
|
|
CN115154440A
(zh)
|
2018-06-27 |
2022-10-11 |
比奥克斯塞尔医疗股份有限公司 |
含右美托咪定的膜制剂及其制造方法
|
|
CN112512509A
(zh)
|
2018-08-02 |
2021-03-16 |
台湾微脂体股份有限公司 |
含有治疗抑郁症或焦虑症的治疗剂的缓释组合物及其用途
|
|
US20200038420A1
(en)
|
2018-08-03 |
2020-02-06 |
Enterin, Inc. |
Aminosterol compositions and methods of using the same for treating depression
|
|
US11154537B2
(en)
|
2018-08-10 |
2021-10-26 |
Eleusis Therapeutics Us, Inc. |
Method of treatment for ketamine infusion
|
|
US12090145B2
(en)
|
2018-08-20 |
2024-09-17 |
Yale University |
Combination therapy for treating or preventing depression or other mood diseases
|
|
EP3628313B1
(en)
*
|
2018-09-28 |
2025-02-12 |
Novohale Therapeutics, LLC |
Ketamine composition for use in a method of treatment of depression by pulmonary administration
|
|
US20210113494A1
(en)
|
2018-10-05 |
2021-04-22 |
Clexio Biosciences Ltd. |
Method Of Treating Post-Traumatic Stress Syndrome
|
|
US20210308040A1
(en)
|
2018-10-26 |
2021-10-07 |
Guangzhou Dazhou Biomedicine Ltd. |
Ketamine oral transmucosal delivery system
|
|
EP3873447A1
(en)
|
2018-10-29 |
2021-09-08 |
Hadasit Medical Research Services and Development Ltd. |
Combination of m-opioid receptor (mor) modulators for preventing and treating pain, suicidality and mental disorders
|
|
MX2021005992A
(es)
|
2018-11-21 |
2021-09-14 |
Certego Therapeutics Inc |
Gaboxadol para reducir el riesgo de suicidio y para alivio rápido de la depresión.
|
|
US11981617B2
(en)
|
2019-01-11 |
2024-05-14 |
Alar Pharmaceuticals Inc. |
Ketamine pamoate and use thereof
|
|
CN113632174B
(zh)
|
2019-01-23 |
2025-03-25 |
密歇根大学董事会 |
用于nmda、甘氨酸和ampa受体的调节剂的药物基因组学决策支持
|
|
US20200261422A1
(en)
|
2019-02-15 |
2020-08-20 |
Massachusetts Institute Of Technology |
Methods for evaluating treatments and physiology in human patients using intravenous alpha-2 adrenergic antagonist agents
|
|
WO2020178653A1
(en)
|
2019-03-05 |
2020-09-10 |
Janssen Pharmaceuticals, Inc. |
Esketamine for the treatment of depression
|
|
EP4230195A1
(en)
|
2019-03-07 |
2023-08-23 |
Arbormentis LLC |
Compositions and methods of use comprising substances with neural plasticity actions administered at non-psychedelic / psychotomimetic dosages and formulations
|
|
US20220143147A1
(en)
|
2019-03-18 |
2022-05-12 |
New York Medical College |
Intranasal neuropeptides for use in stress-related impairments
|
|
JP7453994B2
(ja)
|
2019-04-17 |
2024-03-21 |
エルテーエス ローマン テラピー－ジステーメ アーゲー |
経皮治療システム
|
|
WO2020223701A1
(en)
|
2019-05-02 |
2020-11-05 |
The Broad Institute, Inc. |
Methods for treating neurodevelopmental disorders
|
|
US20220202742A1
(en)
|
2019-05-07 |
2022-06-30 |
Clexio Biosciences Ltd. |
Dosage forms for preventing drug-facilitated assault
|
|
US20220062200A1
(en)
|
2019-05-07 |
2022-03-03 |
Clexio Biosciences Ltd. |
Abuse-deterrent dosage forms containing esketamine
|
|
JP2022541872A
(ja)
|
2019-05-31 |
2022-09-28 |
セロン ファーマ エス．アー． |
医薬組成物の電子的に監督された非経口投与のための吸入器
|
|
KR20220012922A
(ko)
|
2019-05-31 |
2022-02-04 |
셀론 파르마 에스.에이. |
약학적 조성물의 전자적으로 관리된 투여
|
|
US20220257536A1
(en)
|
2019-06-04 |
2022-08-18 |
ADNP Kids Research Foundation |
Ketamine and ketamine/nap for treatment of adnp syndrome and related neurological conditions
|
|
WO2021026232A1
(en)
|
2019-08-05 |
2021-02-11 |
The Ketamine Research Foundation |
Ketamine for the treatment of postpartum symptoms and disorders
|
|
CN114286674A
(zh)
|
2019-08-28 |
2022-04-05 |
杨森制药公司 |
用于治疗患有包括自杀倾向在内的重性抑郁障碍的患者的艾司氯胺酮
|
|
GB201912505D0
(en)
|
2019-08-30 |
2019-10-16 |
Klaria Pharma Holding Ab |
Pharmaceutical formulation
|
|
EP4028085A4
(en)
|
2019-09-13 |
2023-10-04 |
Janssen Pharmaceuticals, Inc. |
INTRANASAL ADMINISTRATION OF ESKETAMINE
|
|
MX2022004022A
(es)
|
2019-10-02 |
2022-05-18 |
Praxis Prec Medicines Inc |
Combinaciones de moduladores alostericos positivos del receptor de gaba-a y antagonistas de nmda, moduladores alostericos negativos de nmda o agonistas parciales de nmda.
|
|
WO2021074448A1
(en)
|
2019-10-18 |
2021-04-22 |
Institute Of Science And Technology Austria |
Stimulation of neuronal plasticity
|
|
WO2021087258A1
(en)
|
2019-10-31 |
2021-05-06 |
The Trustees Of Indiana University |
Compositions and methods for treating alcohol use disorder or a related condition thereof
|
|
WO2021108801A2
(en)
|
2019-11-15 |
2021-06-03 |
Consegna Pharma, Inc. |
Long acting nmda antagonists
|
|
AU2020387937A1
(en)
|
2019-11-18 |
2022-06-02 |
The United States Government As Represented By The Department Of Veterans Affairs |
Salts of (2R, 6R)-hydroxynorketamine, their crystal forms, and methods of making the same
|
|
WO2021101926A1
(en)
|
2019-11-19 |
2021-05-27 |
Stamets Paul Edward |
Tryptamine compositions for enhancing neurite outgrowth
|
|
TW202135787A
(zh)
|
2019-12-12 |
2021-10-01 |
比利時商健生藥品公司 |
艾氯胺酮調配物及製備與儲存的方法
|
|
WO2021121366A1
(en)
|
2019-12-20 |
2021-06-24 |
Alar Pharmaceuticals Inc. |
Long-acting injectable formulations of ketamine pamoate salts
|
|
JP2023507926A
(ja)
|
2019-12-30 |
2023-02-28 |
クレキシオ バイオサイエンシーズ エルティーディー． |
神経精神状態または神経学的状態を治療するためのエスケタミンを用いた投与計画
|
|
IL293506A
(en)
|
2019-12-30 |
2022-08-01 |
Clexio Biosciences Ltd |
Dosage regime with esketamine for treating major depressive disorder
|
|
CN115135317A
(zh)
|
2020-01-22 |
2022-09-30 |
西洛斯治疗有限公司 |
减少nmda拮抗剂的副作用
|
|
DE102020106115A1
(de)
|
2020-03-06 |
2021-09-09 |
Lts Lohmann Therapie-Systeme Ag |
Iontophoretische Zusammensetzung zur Verabreichung von S-Ketamin
|
|
US20210308075A1
(en)
|
2020-04-07 |
2021-10-07 |
Joseph Habboushe |
Prevention and treatment of virial infections
|
|
IL298334A
(en)
|
2020-05-20 |
2023-01-01 |
Certego Therapeutics Inc |
Ring deuterated gaboxadol and its use for the treatment of psychiatric disorders
|
|
CA3180964A1
(en)
|
2020-06-02 |
2021-12-09 |
Yip Hang Eddy Lee |
Methods for treating major depressive disorder and treatment-resistant depression
|
|
WO2021255522A1
(en)
|
2020-06-19 |
2021-12-23 |
Guangzhou Dazhou Biomedicine Ltd. |
Transdermal drug delivery system for ketamine
|
|
US20210401774A1
(en)
|
2020-06-27 |
2021-12-30 |
Robert Brent Turnipseed |
Ketamine protocols and data evaluation for treatment-resistant depression and trauma
|
|
US20220001014A1
(en)
|
2020-07-01 |
2022-01-06 |
Lida Ghaderi |
Compositions and methods for inducing biological mimicry in a mammal for the prevention and/or treatment of covid-19 and other diseases
|
|
US20220040106A1
(en)
|
2020-08-05 |
2022-02-10 |
Thomas Malcolm |
Tailored hypoimmune nanovesicular delivery systems for cancer tumors, hereditary and infectious diseases
|
|
EP3949956A1
(en)
|
2020-08-06 |
2022-02-09 |
LTS Lohmann Therapie-Systeme AG |
Esketamine-suspension-tts
|
|
JP2023538901A
(ja)
|
2020-08-18 |
2023-09-12 |
オークウッド ラボラトリーズ，エル．エル．シー． |
ケタミンを含むマイクロスフェア製剤ならびにその製造及び使用方法
|
|
US20230375561A1
(en)
|
2020-09-30 |
2023-11-23 |
Rima F. Kaddurah-Daouk |
Methods for identification, stratification, and treatment of cns diseases
|
|
EP3995137B1
(de)
|
2020-11-09 |
2024-01-03 |
LTS Lohmann Therapie-Systeme AG |
Oraler dünnfilm
|
|
US20230420110A1
(en)
|
2020-11-18 |
2023-12-28 |
Indiana University Research And Technology Corporation |
Methods for objective assessment, risk prediction, matching to existing medications and new methods of using drugs, and monitoring responses to treatments for mood disorders
|
|
US11382873B1
(en)
|
2021-01-08 |
2022-07-12 |
Vitalis Analgesics LLC |
Oral administration of ketamine
|
|
IL282188A
(en)
|
2021-04-08 |
2022-11-01 |
Yeda Res & Dev |
Combined use of ketamine and bretigabine for the treatment of psychiatric disorders
|
|
US11690811B2
(en)
|
2021-08-13 |
2023-07-04 |
XWPharma Ltd. |
Pharmaceutical compositions and oral dosage forms of ketamine derivatives
|
|
WO2023081109A1
(en)
|
2021-11-05 |
2023-05-11 |
Malcolm Thomas |
Tailored hypoimmune nanovesicular delivery systems for cancer tumors, hereditary and infectious diseases
|
|
US20240009145A1
(en)
|
2022-07-07 |
2024-01-11 |
Vitalis Analgesics LLC |
Compositions of aspirin and ketamine
|